Filtered By:
Specialty: Hematology
Condition: Bleeding
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 643 results found since Jan 2013.
Adverse Events and All-Cause Mortality in Danish Patients with Cerebral Venous Thrombosis: A Nationwide Cohort Study
CONCLUSION: Intracranial bleeding, ischemic stroke, and mortality risks were higher for patients with CVT than matched patients with VTE and the general population, particularly within 6 months after diagnosis.PMID:35688451 | DOI:10.1055/s-0042-1743473
Source: Thrombosis and Haemostasis - June 10, 2022 Category: Hematology Authors: Anne Gulbech Ording Flemming Skj øth S øren Due Andersen Torben Bjerregaard Larsen Source Type: research
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases
ConclusionsIn this real-world analysis of a large sample of NVAF patients with prior bleeding, NOACs were associated with similar or lower risk of stroke/SE and MB vs. warfarin and variable risk of stroke/SE and MB against each other.
Source: Journal of Thrombosis and Thrombolysis - May 17, 2022 Category: Hematology Source Type: research
Clopidogrel monotherapy versus Aspirin monotherapy in patients with established cardiovascular disease: systematic review and meta-analysis
CONCLUSIONS: In patients with established cardiovascular disease, Clopidogrel was associated with a 17% relative-risk reduction for non-fatal MI, borderline decreased risk for MACE and similar risk for all-cause mortality, stroke and major bleeding compared to Aspirin.PMID:35577054 | DOI:10.1055/a-1853-2952
Source: Thrombosis and Haemostasis - May 16, 2022 Category: Hematology Authors: Panagiotis Tasoudis Ioannis Kyriakoulis Dimitrios Sagris Hans-Christoph Diener George Ntaios Source Type: research
Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels
Direct oral anticoagulants (DOACs) do not require routine coagulation monitoring but measuring plasma drug levels may be helpful in specific circumstances. For example, patients with DOAC drug levels below 30 to 50 ng/mL are unlikely to benefit from anticoagulant reversal strategies before an urgent medical procedure or to treat major bleeding [1] or may be suitable candidates for systemic thrombolysis in the setting of acute ischemic stroke [2].
Source: Thrombosis Research - May 12, 2022 Category: Hematology Authors: Siraj Mithoowani, Karen A. Moffat, Akash Gupta, Stephen A. Carlino, Mark A. Crowther Tags: Letter to the Editors-in-Chief Source Type: research
PO-11: Risk of major bleeding in cancer patients with ischemic stroke treated with thrombolysis
Source: Thrombosis Research - May 1, 2022 Category: Hematology Authors: N. Skajaa, K. Adelborg, F.S. Troelsen, C.H. Fuglsang, E. Horv áth-Puhó, H.T. Sørensen Tags: Posters Source Type: research
Prescribing of anticoagulation for atrial fibrillation in primary care
The objective of this study was to describe anticoagulation prescribing by primary care physicians. We conducted an observational study in the Cleveland Clinic Health System among patients with AF and ≥ 1 primary care appointment between 2015 and 2018 and their physicians. We estimated differences in the odds of an eligible patient receiving anticoagulation versus not and a DOAC versus warfarin using two mixed effects logistic regression models, adjusted for patient sociodemographic factor s, history of falls or dementia, and CHA2DS2-VASc and HAS-BLED scores. We categorized physicians into prescribing tertiles, base...
Source: Journal of Thrombosis and Thrombolysis - April 21, 2022 Category: Hematology Source Type: research
Antiplatelet therapy indication in patients also prescribed direct oral anticoagulants
This study highlights the tremendous potential to improve patient safety and reduce bleeding harm.
Source: Journal of Thrombosis and Thrombolysis - April 20, 2022 Category: Hematology Source Type: research
Association of the careggi collateral score with radiological outcomes after thrombectomy for stroke with an occlusion of the middle cerebral artery
AbstractWe aimed to examine the association between Careggi Collateral Score (CCS) and radiological outcomes in a large multicenter cohort of patients receiving thrombectomy for stroke with occlusion of middle cerebral artery (MCA). We conducted a study on prospectively collected data from 1785 patients enrolled in the Italian Registry of Endovascular Treatment in Acute Stroke. According to the extension of the retrograde reperfusion in the cortical anterior cerebral artery-MCA territories, CCS ranges from 0 (absence of retrograde filling) to 4 (visualization of collaterals until the alar segment of the MCA). Radiological ...
Source: Journal of Thrombosis and Thrombolysis - April 8, 2022 Category: Hematology Source Type: research
Effectiveness and safety of apixaban vs. rivaroxaban in patients with atrial fibrillation and type 2 diabetes mellitus
CONCLUSIONS: Among patients with NVAF and T2DM, apixaban was associated with a similar risk of stroke, and a lower risk of major bleeding compared with rivaroxaban.PMID:35292949 | DOI:10.1055/a-1798-2116
Source: Thrombosis and Haemostasis - March 16, 2022 Category: Hematology Authors: Krishna Roy Chowdhury Jonathan Michaud Oriana Hoi Yun Yu Hui Yin Laurent Azoulay Christel Renoux Source Type: research
Atrial fibrillation, liver cirrhosis, thrombosis, and bleeding: A Danish population-based cohort study
CONCLUSION: In patients with AFF, liver cirrhosis was associated with an elevated risk of ischemic stroke, venous thromboembolism, and all evaluated bleeding complications.PMID:35229067 | PMC:PMC8867136 | DOI:10.1002/rth2.12668
Source: Thrombosis and Haemostasis - March 1, 2022 Category: Hematology Authors: Emil B Riahi Kasper Adelborg Lars Pedersen S øren R Kristensen Anette T Hansen Henrik T S ørensen Source Type: research
When and How to Combine Antiplatelet and Anticoagulant Drugs?
Hamostaseologie. 2022 Feb;42(1):73-79. doi: 10.1055/a-1724-4922. Epub 2022 Feb 23.ABSTRACTAntiplatelet and anticoagulant drugs work at different places in the coagulation system. Antiplatelet drugs are usually indicated in patients with atherosclerosis. Anticoagulant drugs are mostly used in patients with atrial fibrillation, venous thromboembolism, or technical heart valves. In some clinical situations, combination of antiplatelet and anticoagulant therapy can be indicated. The most recent situations are a more intensive antithrombotic therapy for risk reduction in patients with atherosclerosis and temporary addition of a...
Source: Hamostaseologie - February 23, 2022 Category: Hematology Authors: Christine Espinola-Klein Source Type: research
